{
    "2019-12-27": [
        [
            {
                "time": "2018-03-15",
                "original_text": "Roche and Gilead Losing Patent Protection on Top Sellers",
                "features": {
                    "keywords": [
                        "Roche",
                        "Gilead",
                        "Patent Protection",
                        "Top Sellers"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2019-01-10",
                "original_text": "Pfizer (PFE) Sees a Difficult 2019: Can it Rebound in 2020?",
                "features": {
                    "keywords": [
                        "Pfizer",
                        "Difficult 2019",
                        "Rebound",
                        "2020"
                    ],
                    "sentiment_score": -0.4,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-12-05",
                "original_text": "Is Mylan (MYL) Doomed to Witness a Terrible 2020 Too?",
                "features": {
                    "keywords": [
                        "Mylan",
                        "Doomed",
                        "Terrible 2020"
                    ],
                    "sentiment_score": -0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2019-12-20",
                "original_text": "Pfizer Is a Top Stock for 2020. Hereâ€™s Why.",
                "features": {
                    "keywords": [
                        "Pfizer",
                        "Top Stock",
                        "2020"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}